NewLink Genetics

NewLink Genetics Corporation (NewLink) is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio includes both biologic and small-molecule immunotherapy product candidates. The Company's biologic product candidates are based on its HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. NewLink's small-molecule product candidates are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-(2, 3)-dioxygenase pathway. Its lead product candidate algenpantucel-L or HyperAcute Pancreas.

Company Growth (employees)
Type
Public
HQ
Ames, US
Founded
1999
Size (employees)
122 (est)-41%
NewLink Genetics was founded in 1999 and is headquartered in Ames, US

NewLink Genetics Office Locations

NewLink Genetics has offices in Ames, Austin and Devens
Ames, US (HQ)
5100 2503 S Loop Dr
Devens, US
108 94 Jackson Rd
Austin, US
100 2700 Vía Fortuna

NewLink Genetics Data and Metrics

NewLink Genetics Financial Metrics

NewLink Genetics's revenue was reported to be $35.8 m in FY, 2016 which is a 48% decrease from the previous period.
USD

Revenue (FY, 2016)

35.8 m

Revenue growth (FY, 2015 - FY, 2016), %

(48%)

Net income (FY, 2016)

(85.2 m)

EBIT (FY, 2016)

(90.8 m)

Market capitalization (21-Jul-2017)

211.4 m

Cash (31-Dec-2016)

131.5 m
NewLink Genetics's current market capitalization is $211.4 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

1.1 m172.6 m68.5 m35.8 m

Revenue growth, %

15691%(60%)(48%)

R&D expense

93.3 m

General and administrative expense

33.2 m

Operating expense total

147.3 m55 m102.1 m126.5 m

EBIT

(138.8 m)117.6 m(33.6 m)(90.8 m)

EBIT margin, %

(12702%)68%(49%)(254%)

Interest expense

33 k26 k105 k22 k

Interest income

12 k86 k78 k237 k

Income tax expense

(130 k)(14.8 m)(6.7 m)5.4 m

Net Income

(136.5 m)102.9 m(40.4 m)(85.2 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

61.3 m190.4 m195.6 m131.5 m

Accounts Receivable

1.3 m3.7 m5.4 m24.5 m

Inventories

5 m5.9 m

Current Assets

64 m230.5 m208.1 m167.9 m

PP&E

6.8 m

Total Assets

70.6 m238.1 m218.5 m174.7 m

Accounts Payable

612 k2.4 m3.7 m22.9 m

Current Liabilities

3.9 m25 m14.8 m37.9 m

Non-Current Liabilities

8.4 m9.3 m7.9 m7.4 m

Total Liabilities

12.2 m34.3 m22.8 m45.3 m

Additional Paid-in Capital

194 m236.8 m276.6 m295.5 m

Retained Earnings

(33.1 m)(80.4 m)(165.5 m)

Total Equity

58.3 m203.8 m195.8 m129.5 m

Financial Leverage

1.2 x1.2 x1.1 x1.3 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(31.2 m)102.9 m(40.4 m)(85.2 m)

Depreciation and Amortization

891 k1.1 m1.6 m2.1 m

Accounts Receivable

1.1 m(2.4 m)(1.7 m)(19.1 m)

Inventories

3.4 m

Accounts Payable

(359 k)7.9 m245 k24.8 m

Cash From Operating Activities

61.3 m109.1 m(24.1 m)(65.9 m)

Purchases of PP&E

(1.4 m)(1.7 m)(4 m)(2.2 m)

Cash From Investing Activities

(141 k)(13.8 m)6.2 m(66 k)

Short-term Borrowings

(154 k)(158 k)

Cash From Financing Activities

67 m33.9 m23.1 m1.9 m

Interest Paid

34 k26 k105 k22 k

Income Taxes Paid

26.4 m4.8 m1 m
Y, 2016

Financial Leverage

1.3 x

NewLink Genetics Market Value History

NewLink Genetics Company Life and Culture

You may also be interested in